Status:

ACTIVE_NOT_RECRUITING

A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Conditions:

Acute Myeloid Leukemia

Eligibility:

All Genders

65-75 years

Phase:

NA

Brief Summary

A subject of major interest for researchers, clinicians, patients, and payers, is the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of these older patients wi...

Detailed Description

Every year, 30,000 patients in Europe and 20,000 in the USA are diagnosed with acute myeloid leukemia (AML). More than half of them are over 65 years old. In this older population, the median overall ...

Eligibility Criteria

Inclusion

  • Men and women
  • Age ≥ 65 and ≤ 75 years
  • Newly diagnosed patients with de novo or secondary AML in first complete remission who are considered as potential candidates and eligible for an allo-HSCT procedure
  • Presence of a donor (matched related or unrelated or haplo-mismatched) willing to donate peripheral blood stem cells
  • Patient is fit for the allo-HSCT procedure
  • Patient is fit for further consolidation therapy (non-transplant arm)
  • Written informed consent

Exclusion

  • Acute promyelocytic leukemia (AML FAB M3)
  • AML deemed not eligible for allo-HSCT
  • Karnofsky score \<70%
  • HIV positive patient
  • Life expectancy less than one month according to the attending physician
  • Acute or chronic heart failure (Cardiac ejection fraction \< 40%)
  • Pulmonary function - diffusion capacity \< 50% predicted
  • Estimated glomerular filtration rate \< 50 ml/min (CKD-EPI)
  • Severe neurological disorders
  • Patient subject to a legal protection measure (guardianship, curatorship and safeguard of justice) or unable to consent
  • Patient deprived of their liberty by a judicial or administrative decision
  • Patient with severe psychiatric disorders or hospitalized without consent for psychiatric care

Key Trial Info

Start Date :

December 31 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2027

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT04822766

Start Date

December 31 2021

End Date

June 1 2027

Last Update

August 13 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Saint Antoine Hospital - Hematology Department

Paris, France, 75012